IRIS
BILO', Maria Beatrice
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.501
EU - Europa 1.462
AS - Asia 452
AF - Africa 31
OC - Oceania 3
SA - Sud America 2
Totale 9.451
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.497
IE - Irlanda 419
SG - Singapore 273
SE - Svezia 236
IT - Italia 235
UA - Ucraina 202
DE - Germania 160
CN - Cina 112
GB - Regno Unito 84
IN - India 51
FR - Francia 45
CI - Costa d'Avorio 25
RU - Federazione Russa 22
BE - Belgio 17
FI - Finlandia 14
HK - Hong Kong 6
PL - Polonia 5
CA - Canada 4
CZ - Repubblica Ceca 4
DK - Danimarca 4
JP - Giappone 4
KR - Corea 4
NL - Olanda 4
AU - Australia 3
MA - Marocco 3
EE - Estonia 2
HR - Croazia 2
ZA - Sudafrica 2
EG - Egitto 1
ES - Italia 1
GR - Grecia 1
HU - Ungheria 1
IR - Iran 1
LT - Lituania 1
NO - Norvegia 1
PE - Perù 1
PK - Pakistan 1
PY - Paraguay 1
RO - Romania 1
RS - Serbia 1
Totale 9.451
Salva come PNG Salva come JPEG
Città #
Des Moines 1.770
Chandler 1.018
Fairfield 535
Jacksonville 455
Ashburn 430
Dublin 417
Houston 325
Boardman 277
Woodbridge 248
Wilmington 245
Cambridge 216
Seattle 200
Lawrence 163
Princeton 163
San Mateo 142
Ann Arbor 123
Redmond 87
Singapore 75
San Diego 65
Washington 60
New York 58
Pune 49
Los Angeles 42
Abidjan 25
London 25
Dallas 23
Centro 19
Beijing 17
Brussels 16
Falls Church 13
Guangzhou 13
Kilburn 13
Norwalk 13
Cedar Knolls 12
Helsinki 12
Rome 11
Shenzhen 9
Ancona 8
Milan 8
Wuhan 8
Shanghai 7
New Bedfont 6
Prescot 6
Squinzano 6
Turin 6
Gatchina 5
Hounslow 5
Phoenix 5
Jinhua 4
Marano Vicentino 4
Pescara 4
Redwood City 4
San Severino Marche 4
St Petersburg 4
Wandsworth 4
Amsterdam 3
Bialystok 3
Civitanova Marche 3
Hangzhou 3
Hong Kong 3
Islington 3
Istia D'ombrone 3
Moscow 3
San Gregorio da Sassola 3
Vallefoglia 3
Yiwu 3
Carmignano 2
Central 2
Edinburgh 2
Genoa 2
Heze 2
Jiaxing 2
Jining 2
Kyoto 2
Montecassiano 2
Monza 2
Napoli 2
Northampton 2
Paris 2
Perm 2
Prague 2
Quanzhou 2
Santa Clara 2
Sioux Falls 2
Southwark 2
Tallinn 2
Tolentino 2
Wuxi 2
Alba 1
Asunción 1
Athens 1
Belgrade 1
Bolzano 1
Boston 1
Brdo 1
Burnaby 1
Callao 1
Catania 1
Catford 1
Cellamare 1
Totale 7.571
Salva come PNG Salva come JPEG
Nome #
Idiopathic anaphylaxis 174
Diagnosing, managing and preventing anaphylaxis: Systematic review 136
Rhinopharyngoscopy, computed tomography and magnetic resonance imaging 124
Safety and Adherence to Venom Immunotherapy During COVID-19 Pandemic 111
Cabbage and fermented vegetables: From death rate heterogeneity in countries to candidates for mitigation strategies of severe COVID-19 108
Sensitization to Cat: Why Not Use Molecular Diagnostics instead of the Nasal Challenge in Clinical Practice? 99
Anaphylaxis in Elderly Patients-Data From the European Anaphylaxis Registry 98
Basal Tryptase High Levels Associated with a History of Arterial Hypertension and Hypercholesterolemia Represent Risk Factors for Severe Anaphylaxis in Hymenoptera Venom-Allergic Subjects over 50 Years Old 97
In vivo diagnosis of allergic diseases - allergen provocation tests 95
Diagnosis of Immediate-Type ß-Lactam Allergy In Vitro by Flow-Cytometric Basophil Activation Test and Sulfi doleukotriene Production: a Multicenter Study. 93
Unmet needs and relationship between general practitioners (GPs) and allergists living in Campania region (southern Italy) 93
Why are allergens not detected in the bronchoalveolar lavage fluid of patients undergoing fiberoptic bronchoscopy? Possible explanations 92
Secondary prevention measures in anaphylaxis patients: Data from the anaphylaxis registry 87
Oxytocin: a likely underestimated risk for anaphylactic reactions in delivering women sensitized to latex 86
Prevention and treatment of hymenoptera venom allergy: Guidelines for clinical practice 84
Phenotype and risk factors of venom-induced anaphylaxis: a case-control study of the European Anaphylaxis Registry 83
Anaphylaxis 83
Immunotherapy for hymenoptera venom allergy: too expensive for European health care? 82
Forced oscillation technique as method to document and monitor the efficacy of mepolizumab in treating severe eosinophilic asthma 80
World Allergy Organization Guidelines for the Assessment and Management of Anaphylaxis 80
Precision Medicine in Hymenoptera Venom Allergy: Diagnostics, Biomarkers, and Therapy of Different Endotypes and Phenotypes 80
Clinical aspects of hymenoptera venom allergy and venom immunotherapy 78
Fatal anaphylaxis in Italy: Analysis of cause-of-death national data, 2004-2016 78
Contraindications to immunotherapy: A global approach 77
Skin test concentrations for systemically administered drugs -- an ENDA/EAACI Drug Allergy Interest Group position paper 77
Is diet partly responsible for differences in COVID-19 death rates between and within countries? 77
Development of a model care pathway for the management of Hymenoptera venom allergy: Evidence-based key interventions and indicators 76
World Allergy Organization survey on global availability of essentials for the assessment and management of anaphylaxis by allergy-immunology specialists in health care settings 76
Severe asthma in adults does not significantly affect the outcome of COVID-19 disease: Results from the Italian Severe Asthma Registry 76
Large local reactions to Hymenoptera stings: outcome of re-stings in real-life 75
Anaphylaxis to baobab fruit: The paradox of “natural healthy food” 75
The natural history and epidemiology of insect venom allergy: clinical implications 75
Anisakis hypersensitivity in Italy: prevalence and clinical features: a multicenter study. 74
Detection of Gibberellin-Regulated Protein (Peamaclein) Sensitization among Italian Cypress Pollen-Sensitized Patients 74
European hornet (Vespa crabro) sting: a new risk factor for life-threatening reaction in hymenoptera allergic patients? 74
Diagnosis of Hymenoptera venom allergy 74
Editorial: Anaphylaxis – A Distinct Immunological Syndrome, but How Much Do We Really Understand? 73
EAACI anaphylaxis guidelines: Systematic review protocol 73
The role of component-resolved diagnosis in Hymenoptera venom allergy 72
Advances in Hymenoptera venom immunotherapy 72
Mast cell diseases and the severity and course of intraoperative anaphylaxis 71
Predictors of side effects during the buildup phase of venom immunotherapy for Hymenoptera venom allergy: the importance of baseline serum tryptase 71
The roadmap for the Allergology specialty and allergy care in Europe and adjacent countries. An EAACI position paper 70
Congruence between international guidelines and mite specific immunotherapy prescribing practices 70
Sublingual immunotherapy with venom is not recommended for patients with Hymenoptera venom allergy 70
Anaphylaxis caused by Hymenoptera stings: from epidemiology to treatment 69
Allergen-specific immunotherapy provides immediate, long-term and preventive clinical effects in children and adults: the effects of immunotherapy can be categorised by level of benefit -the centenary of allergen specific subcutaneous immunotherapy 69
Bonifazi F. Epidemiology of Hymenoptera sting anaphylaxis 68
Risk Factors and Characteristics of Biphasic Anaphylaxis 68
Clinical effectiveness of hymenoptera venom immunotherapy: a prospective observational multicenter study of the European academy of allergology and clinical immunology interest group on insect venom hypersensitivity 67
Allergen immunotherapy for insect venom allergy: protocol for a systematic review 66
Antigen 5 Allergens of Hymenoptera Venoms and Their Role in Diagnosis and Therapy of Venom Allergy 66
A prevalent exposure to male dog is a risk factor for exclusive allergic sensitization to Can f 5: An Italian multicenter study 65
Honeybee venom immunotherapy: a comparative study using purified and nonpurified aqueous extracts in patients with normal Basal serum tryptase concentrations 65
Shedding Light on the Venom Proteomes of the Allergy-Relevant Hymenoptera Polistes dominula (European Paper Wasp) and Vespula spp. (Yellow Jacket) 64
Anxiety and depression in adolescents with asthma and in their parents. Is an increased basal cholinergic tone a possible further reason to explain the negative impact on asthma control? 64
World Allergy Organization anaphylaxis guidelines: Summary 64
The VISYT trial: Venom Immunotherapy Safety and Tolerability with purified vs nonpurified extracts 64
Insect sting anoxic encephalopathy after stopping venom immunotherapy. 64
Hymenoptera Venom Allergy - European Academy of Allergy and Clinical Immunology Monographs 63
The additional values of microarray allergen assay in the management of polysensitized patients with respiratory allergy 63
Purified vs. nonpurified venom immunotherapy 63
Epidemiology of hymenoptera allergy 63
Treating venom allergy during COVID-19 pandemic 63
Anaphylaxis in children and adolescents: The European Anaphylaxis Registry 62
Safety of a 2-day ultrarush immunotherapy in vespid allergic patients: Focus on elevated serum tryptase 62
High long-term efficacy of venom immunotherapy after discontinuation 62
First European data from the network of severe allergic reactions (NORA) 62
International consensus on (ICON) anaphylaxis 62
Use of adrenaline in allergy 62
Hyposensitization therapy of Parietaria-sensitive patients with a tyrosine adsorbed allergoid, Pollinex Parietaria (Bencard Parietaria) 62
Anxiety/depression and impaired asthma control in adolescents. Is an increased basal cholinergic tone a possible link ? 61
Shortness of interval between two stings as risk factor for developing Hymenoptera venom allergy 61
Ves v 5 can establish the diagnosis in patients without detectable specific IgE to wasp venom and a possible north-south difference in Api m 1 sensitization in Europe 61
Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity 61
Oxytocin: an unexpected risk for cardiologic and broncho-obstructive effects, and allergic reactions in susceptible delivering women 61
Epinephrine in Severe Allergic Reactions: The European Anaphylaxis Register 60
Omalizumab in chronic spontaneous urticaria: patient-tailored tapering or planned discontinuation? 60
Hymenoptera Venom Immunotherapy: How to Safely Switch to the Same Venom From a Different Manufacturer 59
Clonal mast cell disorders in patients with severe Hymenoptera venom allergy and normal serum tryptase levels 59
CAP-Inhibition, Molecular Diagnostics, and Total IgE in the Evaluation of Polistes and Vespula Double Sensitization 58
High adherence to hymenoptera venom subcutaneous immunotherapy over a 5-year follow-up: A real-life experience 58
European Polistes venom allergy 58
Reducing the risk of anaphylaxis during anesthesia: 2011 updated guidelines for clinical practice 58
Lysozyme, a new allergen in donkey's milk 57
Anaphylactic Reactions After Discontinuation of Hymenoptera Venom Immunotherapy: A Clonal Mast Cell Disorder Should Be Suspected 57
Sublingual immunotherapy with venom for patients with Hymenoptera venom allergy Reply 57
Component resolved diagnosis in real life: the risk assessment of food allergy using microarray-based immunoassay 57
Efficacy of a single dose of omalizumab for the prevention of ethylene oxide intraoperative anaphylaxis 56
Honeybee venom immunotherapy: certainties and pitfalls 56
Diagnosis of immediate-type beta-lactam allergy in vitro by flow-cytometric basophil activation test and sulfidoleukotriene production: a multicenter study 56
Efficacy of an air‐cleaning device equipped with a high efficiency particulate air filter in house dust mite respiratory allergy 55
Risk of severe anaphylaxis for patients with Hymenoptera venom allergy: Are angiotensin-receptor blockers comparable to angiotensin-converting enzyme inhibitors? Reply 55
Allergen immunotherapy for insect venom allergy: a systematic review and meta-analysis 54
Adherence to the rhinitis management plan of allergic rhinitis 54
Vespid allergy 54
2012 Update: World Allergy Organization Guidelines for the assessment and management of anaphylaxis 54
Factors increasing the risk for a severe reaction in anaphylaxis: An analysis of data from The European Anaphylaxis Registry 53
EAACI Food Allergy and Anaphylaxis Guidelines Group. Management of anaphylaxis: a systematic review 53
Research needs in allergy: an EAACI position paper, in collaboration with EFA 53
Totale 7.171
Salva come PNG Salva come JPEG
Categoria #
all - tutte 56.160
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 56.160
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020550 0 4 8 3 51 96 33 8 51 6 122 168
2020/20212.127 116 179 260 87 430 113 114 180 191 143 221 93
2021/20221.200 61 235 18 35 21 69 46 94 106 75 132 308
2022/20234.055 228 212 169 261 177 1.998 1 167 588 23 166 65
2023/20241.392 268 39 119 139 223 271 23 46 7 53 19 185
2024/2025326 100 226 0 0 0 0 0 0 0 0 0 0
Totale 9.729